Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) ...
US FDA expands use of Bristol Myers' cancer therapy
The U.S. Food and Drug Administration on Thursday expanded the use of Bristol Myers Squibb's cell therapy, Breyanzi, for a type of slow-growing blood cancer, marking the second approval for the tre...
Get Paid To Wait: 13 Potential Dividend Opportunities
The Efficient Market Hypothesis states that the stock market is efficiently priced, and therefore it is impossible to consistently generate alpha.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies
The U.S. Food and Drug Administration's staff reviewers on Wednesday raised safety concerns over the use of Johnson & Johnson's and Bristol-Myers Squibb's cancer therapies as earlier treatments for...
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024.
5 Top Dividend Stocks Passive Income Investors Should Buy in March
Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.
Bristol-Myers Squibb: Finally Trending Up
Bristol-Myers Squibb has returned to sales growth after a period of declining sales, signaling a turnaround ahead. The biopharma continues to be hit by key drugs facing LOEs, but new drugs and acqu...
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Upcoming Investor Conferences.
Millionaire's Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town
If you're searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out.
Dividend Stocks That Could Deliver Life-Changing Returns
2022 was a dreadful year for investors, with the S&P 500 down almost 20% and the Nasdaq lower by a stunning 33%.
Bristol Myers CEO says India to have largest R&D presence outside US by 2025
Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025, CEO Chri...
Related Companies